{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:22:51Z","timestamp":1788967371121,"version":"build-2803163510"},"reference-count":10,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"<jats:p>This economic evaluation investigated the budget impact associated with gene therapy treatment of autosomal recessive dystrophic epidermolysis bullosa.<\/jats:p>","DOI":"10.1001\/jamadermatol.2026.3240","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:39Z","timestamp":1788966039000},"source":"Crossref","is-referenced-by-count":0,"title":["Budget Impact Analysis of Gene Therapies for Recessive Dystrophic Epidermolysis Bullosa"],"prefix":"10.1001","author":[{"given":"Adam J. N.","family":"Raymakers","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Clinical Immunology, and Allergy, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"dld260023r1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-5-12","article-title":"Inherited epidermolysis bullosa.","volume":"5","author":"Fine","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"dld260023r2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.17012","article-title":"Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB registry: EB more common than previously assumed?","volume":"35","author":"Baardman","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"dld260023r3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2133.2002.04607.x","article-title":"The clinical spectrum of dystrophic epidermolysis bullosa.","volume":"146","author":"Horn","year":"2002","journal-title":"Br J Dermatol"},{"issue":"3","key":"dld260023r4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1001\/jamadermatol.2023.5857","article-title":"Estimated spending on beremagene geperpavec for dystrophic epidermolysis bullosa.","volume":"160","author":"Raymakers","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dld260023r5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"issue":"5","key":"dld260023r6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices\u2014budget impact analysis.","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"issue":"11","key":"dld260023r9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","article-title":"Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry.","volume":"152","author":"Fine","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7","key":"dld260023r10","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxaf132","article-title":"What drug characteristics explain the wide range of manufacturer rebates?","volume":"3","author":"Beinfeld","year":"2025","journal-title":"Health Aff Sch"},{"key":"dld260023r7","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017","edition":"4th ed"},{"key":"dld260023r8","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual. Accessed August 3, 2026. https:\/\/www.nice.org.uk\/process\/pmg36"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853490\/jamadermatology_raymakers_2026_ld_260023_1787587991.93698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:41Z","timestamp":1788966041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3240","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}